Research

Hormonal

Weekly subcutaneous semaglutide (up to 2.4 mg) reduces BMI, HbA1c, and blood pressure, and improves self-rated quality of life in patients with schizophrenia or schizoaffective disorder and obesity.

For patients with schizophrenia or schizoaffective disorder and obesity, weekly semaglutide injections (up to 2.4 mg) can effectively reduce weight, improve blood sugar control, and lower blood pressure, while also improving quality of life. This treatment is feasible in inpatient settings, even for those with severe mental illness, though side effects like nausea may lead some to discontinue. It should be considered as part of a comprehensive care plan including dietary advice.

ModerateSupportsMEDIUM confidence
In this feasibility study, weekly semaglutide treatment was associated with improvement in self-rated overall QOL and reductions in BMI, HbA1c and blood pressure at up to 6 months follow-up.
Adrian Heald et al. · Advances in Therapy · 2025

Why this rating

The study is a small, short-term feasibility study (n=15, up to 6 months) without a control group, limiting generalizability and causal inference.

Source

Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss

Adrian Heald et al. · Advances in Therapy · 2025

DOI 10.1007/s12325-025-03261-0

case_series · n=15Cited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →